Neumedicines Inc. Receives Notice of Allowance for Patent Covering Use of HemaMax™ (rIL-12) to Treat

Neumedicines Inc. Receives Notice of Allowance for Patent Covering Use of HemaMax™ (rIL-12) to Treat Chemotherapy-Induced Thrombocytopenia (CIT) Neumedicines Inc. receives Notice of Allowance from the USPTO, providing coverage for methods of using HemaMax™ to treat chemotherapy-induced thrombocytopenia (CIT), a condition of lower than normal platelet counts caused by the hematologically toxic side effects of chemotherapy. Pasadena, CA (PRWEB) January 31, 2011 Neumedicines Inc., a biotechnology company developing therapies for applications in oncology and hematology, today announced that
Contributor
PR Web
PR Web
Lanham, Maryland
Law Marketing
1.800.345.5572
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Download

Related Documents in PR Web
MCLE Sales

Categories